Kura Drug Patent Portfolio
Kura owns 1 orange book drug protected by 8 US patents Given below is the list of Kura's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12410184 | Crystalline Forms Of A Menin Inhibitor | 16 Jul, 2044 | Active |
| US12521396 | Pharmaceutical Compositions Comprising A Menin Inhibitor | 16 Jul, 2044 | Active |
| US11944627 | Methods For Treating Hematological Malignancies And Ewing'S Sarcoma | 06 Sep, 2038 | Active |
| US10781218 | Substituted Inhibitors Of Menin-Mll And Methods Of Use | 15 Mar, 2037 | Active |
| US11673898 | Substituted Inhibitors Of Menin-Mll And Methods Of Use | 15 Mar, 2037 | Active |
| US10869868 | Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression In Npm1 Mutant Leukemia | 26 Jan, 2037 | Active |
| US10077271 | Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins | 16 Mar, 2036 | Active |
| US10174041 | Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins | 16 Mar, 2036 | Active |
Latest Legal Activities on Kura's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kura.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 20 Jan, 2026 | US12521396 |
| Recordation of Patent eGrant | 13 Jan, 2026 | US12521396 |
| Email Notification | 13 Jan, 2026 | US12521396 |
| Initial letter Re: PTE Application to regulating agency | 13 Jan, 2026 | US10077271 |
| Patent eGrant Notification | 13 Jan, 2026 | US12521396 |
| Mail Patent eGrant Notification | 13 Jan, 2026 | US12521396 |
| Patent Issue Date Used in PTA Calculation | 13 Jan, 2026 | US12521396 |
| Initial letter Re: PTE Application to regulating agency | 13 Jan, 2026 | US10781218 |
| Patent Term Extension Application under 35 USC 156 Filed | 06 Jan, 2026 | US10781218 |
| Patent Term Extension Application under 35 USC 156 Filed | 06 Jan, 2026 | US10077271 |
| Email Notification | 01 Jan, 2026 | US12521396 |
| Issue Notification Mailed | 30 Dec, 2025 | US12521396 |
| Dispatch to FDC | 18 Dec, 2025 | US12521396 |
| Application Is Considered Ready for Issue | 18 Dec, 2025 | US12521396 |
| Issue Fee Payment Verified | 17 Dec, 2025 | US12521396 |
Kura's Family Patents
Clinical Trials
Recent Clinical Trials by Kura:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Kura Oncology, Inc. | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Kura Oncology, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Kura Oncology, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Kura Oncology, Inc. | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |
Kura Drug List
Given below is the complete list of Kura's drugs and the patents protecting them.
1. Komzifti
Komzifti is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12410184 | Crystalline Forms Of A Menin Inhibitor |
16 Jul, 2044
(17 years from now)
| Active |
| US12521396 | Pharmaceutical Compositions Comprising A Menin Inhibitor |
16 Jul, 2044
(17 years from now)
| Active |
| US11944627 | Methods For Treating Hematological Malignancies And Ewing'S Sarcoma |
06 Sep, 2038
(11 years from now)
| Active |
| US10781218 | Substituted Inhibitors Of Menin-Mll And Methods Of Use |
15 Mar, 2037
(10 years from now)
| Active |
| US11673898 | Substituted Inhibitors Of Menin-Mll And Methods Of Use |
15 Mar, 2037
(10 years from now)
| Active |
| US10869868 | Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression In Npm1 Mutant Leukemia |
26 Jan, 2037
(10 years from now)
| Active |
| US10077271 | Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins |
16 Mar, 2036
(9 years from now)
| Active |
| US10174041 | Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins |
16 Mar, 2036
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Komzifti's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List